A Phase 3 interventional study of TAK-438 and TAK-438 in Erosive Esophagitis, sponsored by Takeda. Completed at 32 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-11-05.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.
Among the 10 studies testing vonoprazan in Esophagitis, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 1st registered.
123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.
Browse Esophagitis studies →1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 18+
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2011.
This study's enrollment of 305 is above the median of 96 across 99 interventional studies indexed under Esophagitis.
Median enrollment 357 across the 10 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
11 studies in Esophagitis by Takeda: none open now, none under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 11 studies in Esophagitis by Takeda, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.
Takeda’s Esophagitis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing vonoprazan in Esophagitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 11 in Esophagitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety of long term use of TAK-438, once daily (QD), for the maintenance treatment of healed erosive esophagitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have successfully completed the preceding phase 3 double-blind study (TAK-438/CCT-002: preceding study) and have endoscopically healed EE at Week 2, 4, or 8 in the preceding study.*
* "Endoscopically healed EE" is defined as those participants who have endoscopically confirmed EE of Grade O as defined by the Los Angeles (LA) Classification Grading System.
Exclusion Criteria:
Drug: TAK-438
Drug: TAK-438
Incidence of Treatment-emergent Adverse Events
Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through the last visit.
Time frame: 52 Weeks
Change from Baseline in Laboratory Values
Time frame: Baseline and Week 52
Change from Baseline in Electrocardiograms
Time frame: Baseline and Week 52
Change from Baseline in Vital Signs
Time frame: Baseline and Week 52
Change from Baseline in Serum Gastrin
Time frame: Baseline and Week 52
Change from Baseline in Pepsinogen I and II
Time frame: Baseline and Week 52
Endoscopically confirmed recurrence rate of Erosive Esophagitis
Time frame: 52 Weeks
The record gives a start of Sep 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan